Portilla A G, Sugarbaker P H, Chang D
The Washington Cancer Institute, Washington Hospital Center, 110 Irving Street NW, Washington, DC 20010, USA.
World J Surg. 1999 Jan;23(1):23-9. doi: 10.1007/s002689900560.
Assuming that peritoneal carcinomatosis is a local/regional dissemination of disease, a treatment strategy utilizing cytoreductive surgery and intraperitoneal chemotherapy was developed to treat colon cancer. In an attempt to improve knowledge of the mechanisms controlling abdominal and pelvic recurrences and for better selection of patients for reoperation, we studied those patients who had a second-look surgery following cytoreduction for peritoneal carcinomatosis from colorectal cancer. A group of 18 patients with symptoms and signs of recurrent peritoneal carcinomatosis were treated with reoperative surgery after definitive cytoreduction and intraperitoneal chemotherapy. An analysis of clinical features of these patients was performed using survival as an endpoint for evaluation of prognosis. The data suggest that the clinical features to be used to select patients for a second-look procedure after prior cytoreduction were the completeness of resection at the time of initial cytoreduction (p = 0.04) and the completeness of resection at the time of the second look (p = 0.066). In addition, a limited extent of peritoneal carcinomatosis distribution found at the time of the second look predicted a favorable result. A new objective assessment of peritoneal carcinomatosis, the peritoneal cancer index, was found to be of help during patient selection (p = 0.066). We concluded that second-look surgery with potential curative intent should be considered in patients who had a complete initial cytoreduction and those in whom total removal of the recurrence is judged possible at the time of the second look. At the time of abdominal exploration, a limited distribution and volume of peritoneal carcinomatosis as defined by the peritoneal cancer index should be considered. Palliative debulking procedures should be used to alleviate symptoms in other patients.
假设腹膜癌病是疾病的局部/区域扩散,一种利用细胞减灭术和腹腔内化疗的治疗策略被开发用于治疗结肠癌。为了增进对控制腹部和盆腔复发机制的了解,并更好地选择再次手术的患者,我们研究了那些因结直肠癌腹膜癌病接受细胞减灭术后进行二次探查手术的患者。一组18例有复发性腹膜癌病症状和体征的患者在确定性细胞减灭术和腹腔内化疗后接受了再次手术。以生存作为评估预后的终点,对这些患者的临床特征进行了分析。数据表明,用于选择先前细胞减灭术后进行二次探查手术患者的临床特征是初次细胞减灭时的切除完整性(p = 0.04)和二次探查时的切除完整性(p = 0.066)。此外,二次探查时发现的腹膜癌病分布范围有限预示着良好的结果。一种新的腹膜癌病客观评估指标——腹膜癌指数,在患者选择过程中被发现有帮助(p = 0.066)。我们得出结论,对于初次细胞减灭术完全切除且二次探查时判断有可能完全切除复发灶的患者,应考虑进行有潜在治愈意图的二次探查手术。在腹部探查时,应考虑腹膜癌指数所定义的腹膜癌病分布有限且体积较小的情况。对于其他患者,应采用姑息性肿瘤减积手术来缓解症状。